Evidence map›Paper›PMID 32347575›Full record

ArticleThe EMBO journal2020

BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites.

Zhaohua Hu, Shaojie Mi, Ting Zhao, Changmin Peng, Yihan Peng, Lulu Chen, Wenge Zhu, Yi Yao, Qibin Song, Xiangpan Li and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 47 citations in OpenAlex.

  1. iScience · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Zhaohua Hu *State Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, China.
Shaojie Mi *Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Ting Zhao *State Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, China.
Changmin PengDepartment of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, USA.ORCID 0000-0002-7589-661X
Yihan PengDepartment of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, USA.
Lulu ChenCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Wenge ZhuDepartment of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, USA.
Yi YaoCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Qibin SongCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Xiangpan LiCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Xinzhi LiDepartment of Orthopedics, Affiliated Renhe Hospital of China Three Gorges University, Yichang, Hubei, China.
Chenxi JiaState Key Laboratory of Proteomics, National Center for Protein Sciences Beijing, Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, China.
Huadong PeiDepartment of Biochemistry and Molecular Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, USA.ORCID 0000-0002-3764-9060
George Washington University · USWuhan University · CNBeijing Proteome Research Center · CNChina Three Gorges University · CNTianjin University of Science and Technology · CN

Funding

The Role of And-1 in DNA Damage ResponseR01CA177898 · NCI · GEORGE WASHINGTON UNIVERSITY · PI ZHU, WENGE · 2014 to 2018
$1.6M
The Regulation of Cisplatin resistance in ovarian cancerR01CA184717 · NCI · GEORGE WASHINGTON UNIVERSITY · PI ZHU, WENGE · 2014 to 2018
$1.6M
American Cancer Society (ACS) RSG-19-032-01-DMCNCI NIH HHS R01 CA177898NCI NIH HHS R01 CA184717
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are emerging regulators of genomic stability and human disease. However, the molecular mechanisms by which nuclear lncRNAs directly contribute to DNA damage responses remain largely unknown. Using RNA antisense purification coupled with quantitative mass spectrometry (RAP-qMS), we found that the lncRNA BGL3 binds to PARP1 and BARD1, exhibiting unexpected roles in homologous recombination. Mechanistically, BGL3 is recruited to DNA double-strand breaks (DSBs) by PARP1 at an early time point, which requires its interaction with the DNA-binding domain of PARP1. BGL3 also binds the C-terminal BRCT domain and an internal region (amino acids 127-424) of BARD1, which mediates interaction of the BRCA1/BARD1 complex with its binding partners such as HP1γ and RAD51, resulting in BRCA1/BARD1 retention at DSBs. Cells depleted for BGL3 displayed genomic instability and were sensitive to DNA-damaging reagents. Overall, our findings underscore the biochemical versatility of RNA as a mediator molecule in the DNA damage response pathway, which affects the accumulation of BRCA1/BARD1 at DSBs.

Indexed as

DNA Breaks, Double-StrandedDNA DamageBRCA1 ProteinHEK293 CellsHumansMCF-7 CellsMultiprotein ComplexesPoly (ADP-Ribose) Polymerase-1Protein DomainsRNA, Long NoncodingTumor Suppressor ProteinsUbiquitin-Protein LigasesBARD1 protein, humanBRCA1 ProteinBRCA1 protein, humanMultiprotein ComplexesPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1RNA, Long NoncodingTumor Suppressor ProteinsUbiquitin-Protein LigasesBGL3BRCA1/BARD1homologous recombination repairLncRNA

Identifiers

PMID32347575
PMCPMC7298298
OpenAlexW3019416780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.